In our ClinSeq study, nine HER2-positive patients harbored amplification in TOP2A. Another “late phase” breast cancer study39, showed HER2-positive patients with a hyperactive PI3K pathway, defined by somatic mutations in PIK3CA, to benefit from the addition of everolimus to their therapy regimen. Here, TOP2A is linked to breast carcinoma.